https://www.avient.com/sites/default/files/2020-05/2.-polyone-ir-presenstation-wells-fargo-industrials-conference.pdf
Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8
P E O P LE
P RO D U CT S P LA N E T
P E RF O R MAN C E
JVs Performance Products & Solutions Distribution Specialty
To be the world’s
premier provider of
specialized polymer
materials, services and
solutions
To be the world’s
premier provider of
specialized polymer
materials, services
and sustainable
solutions
2016 2017 2018 2019
Lightweighting Reduced Material Requirements Improved Recyclability
Renewable Energy Applications Eco-conscious Bio-derived Content
Reduced Energy Use VOC Reduction
$275M
$325M
$355M
$410M 14% Total Annual Growth
9% Organic Annual Growth
PolyOne Corporation 33
Adjusted EPS attributable to PolyOne common shareholders is calculated as follows:
2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018***
Q1
2019*** 2019
Q1
2020
Net income from continuing operations attributable to PolyOne
common shareholders
Joint venture equity earnings, after tax
Special items, before tax(1)
Special items, tax adjustments(1)
Adjusted net income from continuing operations attributable to
PolyOne common shareholders
$ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1
(19.0) (14.7) (3.7) — — — — — — — — — — —
(48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6
(27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0)
$ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7
Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7
Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48
* Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation.
** Pro forma for sale of Designed Structures and Solutions segment (DSS).
*** Pro forma for sale of Performance Products and Solutions segment (PP&S).
https://www.avient.com/sites/default/files/2022-09/Cesa Aversive Product Bulletin.pdf
Longer lasting protection can help
avoid unplanned service breakdowns and associated
high costs for repairing or installing brand new
replacement cables.
TECHNOLOGY BENEFITS
• Helps provide long term cable protection against
rats and termites
• Enables manufacturers and cable users to be
compliant with EU Regulations
• Easy to use, direct incorporation in the jacket,
no need for additional layer to protect the cable
• Helps avoid unplanned service breakdowns
with associated high repair costs
1 CA-Sept15-Doc.6.2- Final
2 A masterbatch should be regarded as a biocidal product if it is has a biocidal function.
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Bio-based Polymer Solutions Application Bulletin.pdf
KEY CHARACTERISTICS
• Available for polyethylene, polypropylene, ABS,
polycarbonate and styrenics
• Bio-content of resin carrier varies from 70% to
100% depending on polymer—calculated to
ASTM D6866 standard
• Manufactured at four ISO 13485 certified sites,
providing global consistency and security of
supply
• Documented change control beyond CAS
number, reducing risk of change
• Drop-in solutions that can be processed like
fossil-based grades on common injection
molding and extrusion machines
• Can be provided as ready-to-use pre-colored
or additive formulation
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1
- USP and (incl. class VI)
- European Pharmacopeia, monograph 3.1.3/
3.1.5 (polyolefin packaging materials)
- USP (polyethylene)
- Elemental impurities as per ICH Q3D
• Registered Drug Master File (Type III) and/or
Device Master File
• Food contact according to US FDA and
APPLICATION BULLETIN
Sustainability Spotlight
Bio-polymers
Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2023-03/Mevopur Healthcare Functional Additives Nucleating Application Bulletin.pdf
REGULATORY SUPPORT
• Drug delivery devices
• Pharmaceutical packaging
• Medical equipment
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified sites,
providing global consistency and increased
security of supply
• Documented change control beyond CAS
number level, reducing the risk of change
• Allows crystallization in semi-crystalline
polymers to begin faster and complete earlier
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III) and/or
Device Master File
• Food contact established with FDA/EU*
APPLICATION BULLETIN
* FDA/EU compliance information available upon request
Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2023-05/Mevopur Healthcare Colorants and Formulations Amber for Pharma Application Bulletin.pdf
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified sites,
providing global consistency and increased
security of supply
• Documented change control beyond CAS
number level, reducing risk of change
• Non-phthalate and formulated without
animal-derived substances
• Different tones of amber available on request
—more or less red or yellow and/or lighter
or darker
• Also available in liquid form
REGULATORY SUPPORT
• Pre-tested raw materials:
- ISO 10993-1 and USP parts
(Class VI)
- European Pharmacopeia, monograph
3.1.15, USP and elemental analysis
as per ICH Q3D
- USP criteria appearance of solution,
color
• Registered Drug Master File (Type III) by
the FDA
• Food contact compliance established with
FDA/EU*
• YBB00102002-2015 (oral liquid pharmaceutical
PET bottles) compliance support
APPLICATION BULLETIN
* FDA/EU compliance
information available
upon request
Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2022-12/Renol Fiber Colorants Black Colorants for PET and PA Fibers Product Bulletin.pdf
KEY CHARACTERISTICS
• Excellent lot-to-lot and within-lot consistency for
high-quality homogeneous black shades
• Easy processing and support of a long-lasting
spin pack lifetime
• Fastness properties and specification tolerances
on par with high-end products on the market
• Standard and bluish undertones available
in high pigment loadings for an efficient and
competitive coloration package
• Can be combined with additives into a single
combination concentrate for convenience
• Compliance with global, regional, and local
standards and regulations*
RECOMMENDED USE
• In most cases, the concentrate is added
directly to the resin using gravimetric or
volumetric dosing units; for some processes,
the concentrate can be added via a side stream
extruder (direct spinning)
• The recommended dosages are from 3% for
the typical automotive, technical, and carpet
applications and up to 6% for apparel, footwear,
and home textile yarns
* Contact your local sales representative for more information on
regulatory compliance
PRODUCT BULLETIN
Copyright © 2022, Avient Corporation.
https://www.avient.com/sites/default/files/2020-09/oncolor-hc-product-bulletin-1.pdf
OnColor HC Colorants support OEM’s, processors
and converters in achieving global regulatory
compliance and meeting performance demands
under today’s strict sterilization methods.
https://www.avient.com/sites/default/files/2024-11/Ballistic Panel Infographic.pdf
Source: Lucintel Growth Opportunities in the Global Ballistic Composites Market 2023-2028
What’s driving their adoption?
https://www.avient.com/sites/default/files/2021-12/MagIQ Nonwoven Electret for HEPA Application Bulletin.pdf
AVAILABILITY
MagIQ™ Nonwoven Electret additives for HEPA filters
are available globally and are supplied from Asia
and Europe.
https://www.avient.com/sites/default/files/2023-03/Mevopur Healthcare Functional Additives Antistatic Application Bulletin_0.pdf
APPLICATIONS
• Medical devices
• Drug delivery devices
• Labware
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified sites,
providing global consistency and increased
security of supply
• Documented change control beyond CAS
number level, reducing risk of change
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP
biological evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III) and/or
Device Master File
• Food contact established with FDA/EU*
* FDA/EU compliance information available upon request
Copyright © 2023, Avient Corporation.